Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome
Sign Up to like & getrecommendations! Published in 2023 at "Cancer"
DOI: 10.1002/cncr.34722
Abstract: Patients with cytopenic myelofibrosis (MF) have more limited therapeutic options and poorer prognoses compared with patients with the myeloproliferative phenotype. read more here.
Keywords: myelofibrosis response; response toxicity; ruxolitinib cytopenic; cytopenic myelofibrosis ... See more keywords